Revisiting skeletal myopathy and exercise training in heart failure: Emerging role of myokines.

[1]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[2]  Ian R. Lanza,et al.  Exerkines in health, resilience and disease , 2022, Nature Reviews Endocrinology.

[3]  Saumya Das,et al.  lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth , 2022, Circulation.

[4]  R. Geffers,et al.  Skeletal muscle derived Musclin protects the heart during pathological overload , 2022 .

[5]  K. Højlund,et al.  Factors mediating exercise‐induced organ crosstalk , 2022, Acta physiologica.

[6]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.

[7]  R. D. de Boer,et al.  Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure? , 2021, European journal of heart failure.

[8]  J. Vederas,et al.  Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists , 2021, Peptides.

[9]  Sanjiv J. Shah,et al.  Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. , 2021, Journal of the American College of Cardiology.

[10]  L. Ferrucci,et al.  International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines , 2021, The journal of nutrition, health & aging.

[11]  Daowen Wang,et al.  Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure , 2021, Frontiers in Physiology.

[12]  R. Ramírez‐Vélez,et al.  Heart failure-related skeletal myopathy. Potential involvement of myokines. , 2021, Revista espanola de cardiologia.

[13]  M. Izquierdo,et al.  Physical activity guidelines for older people: knowledge gaps and future directions. , 2021, The Lancet. Healthy longevity.

[14]  R. Qaisar,et al.  Prediction of sarcopenia using a battery of circulating biomarkers , 2021, Scientific Reports.

[15]  C. Phillips,et al.  Deciphering Myostatin’s Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases , 2021, Frontiers in Genetics.

[16]  I. Piña,et al.  Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel. , 2021, Journal of the American College of Cardiology.

[17]  C. Drevon,et al.  Progress and Challenges in the Biology of FNDC5 and Irisin , 2021, Endocrine reviews.

[18]  M. Lichtenauer,et al.  Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes , 2021, Disease markers.

[19]  Jun Ma,et al.  The role of Irisin in multiorgan protection , 2021, Molecular Biology Reports.

[20]  B. Dallagiovanna,et al.  Long Non-coding RNAs Are Differentially Expressed After Different Exercise Training Programs , 2020, Frontiers in Physiology.

[21]  M. Koutsilieris,et al.  Heart Failure–Induced Skeletal Muscle Wasting , 2020, Current Heart Failure Reports.

[22]  M. Obokata,et al.  Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies. , 2020, Heart failure clinics.

[23]  S. Zhuang,et al.  Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (Leprdb) Mice , 2020, Frontiers in Pharmacology.

[24]  H. Sabe,et al.  Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets , 2020, Frontiers in Cardiovascular Medicine.

[25]  R. Wachter,et al.  Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials , 2020, European journal of heart failure.

[26]  B. Pedersen,et al.  Muscle–Organ Crosstalk: The Emerging Roles of Myokines , 2020, Endocrine reviews.

[27]  S. M. Barbalho,et al.  Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications , 2020, International journal of molecular sciences.

[28]  P. Schlattmann,et al.  Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction , 2020, Circulation. Heart failure.

[29]  T. Powrózek,et al.  Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure , 2020, Journal of clinical medicine.

[30]  C. Moro,et al.  Exercise-Released Myokines in the Control of Energy Metabolism , 2020, Frontiers in Physiology.

[31]  J. Baker,et al.  The effects of concurrent training order on body composition and serum concentrations of follistatin, myostatin and GDF11 in sarcopenic elderly men , 2020, Experimental Gerontology.

[32]  J. Hawley,et al.  Mimicking exercise: what matters most and where to next? , 2019, The Journal of physiology.

[33]  K. Cheng,et al.  Exercise protects the heart against myocardial infarction through upregulation of miR-1192. , 2019, Biochemical and biophysical research communications.

[34]  Bin Zhu,et al.  Myokines: An Available Biomarker to Evaluate Cardiac Functions? , 2019, Cardiology.

[35]  Pingan Chen,et al.  Predictive value of serum myostatin for the severity and clinical outcome of heart failure. , 2019, European journal of internal medicine.

[36]  P. Ponikowski,et al.  The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study , 2019, European journal of heart failure.

[37]  R. Arena,et al.  Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[38]  H. Galal,et al.  SERUM IRISIN LEVEL IN MYOCARDIAL INFARCTION PATIENTS WITH OR WITHOUT HEART FAILURE. , 2019, Canadian journal of physiology and pharmacology.

[39]  R. Piccirillo.  Exercise-Induced Myokines With Therapeutic Potential for Muscle Wasting , 2019, Front. Physiol..

[40]  K. Alitalo,et al.  Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  F. Guidi,et al.  Circulating irisin levels in heart failure with preserved or reduced ejection fraction: A pilot study , 2019, PloS one.

[42]  Yu Han,et al.  Irisin Protects Heart Against Ischemia-Reperfusion Injury Through a SOD2-Dependent Mitochondria Mechanism , 2018, Journal of cardiovascular pharmacology.

[43]  Kathleen E. Allen,et al.  Lifestyle Modifications for Preventing and Treating Heart Failure. , 2018, Journal of the American College of Cardiology.

[44]  M. Batista,et al.  Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases , 2018, Front. Physiol..

[45]  D. Forman,et al.  Impaired Exercise Tolerance in Heart Failure: Role of Skeletal Muscle Morphology and Function , 2018, Current Heart Failure Reports.

[46]  S. Anker,et al.  Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) , 2018, European journal of heart failure.

[47]  N. Tatonetti,et al.  Structural and functional cardiac profile after prolonged duration of mechanical unloading: potential implications for myocardial recovery. , 2018, American journal of physiology. Heart and circulatory physiology.

[48]  Alejandro Lucia,et al.  Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors , 2018, Nature Reviews Cardiology.

[49]  J. Lan,et al.  Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway. , 2018, Journal of molecular and cellular cardiology.

[50]  M. Cesari,et al.  The exerkine apelin reverses age-associated sarcopenia , 2018, Nature Medicine.

[51]  F. Uzun,et al.  Adropin and Irisin in Patients with Cardiac Cachexia , 2018, Arquivos brasileiros de cardiologia.

[52]  Da-Zhi Wang,et al.  Non-coding RNAs and exercise: pathophysiological role and clinical application in the cardiovascular system. , 2018, Clinical science.

[53]  L. Padeletti,et al.  Exercise and heart failure: an update , 2017, ESC heart failure.

[54]  P. Li,et al.  Irisin inhibits high glucose‐induced endothelial‐to‐mesenchymal transition and exerts a dose‐dependent bidirectional effect on diabetic cardiomyopathy , 2017, Journal of cellular and molecular medicine.

[55]  K. Matthews,et al.  Absence of Myostatin Improves Cardiac Function Following Myocardial Infarction. , 2017, Heart, lung & circulation.

[56]  S. Anker,et al.  Muscle wasting and cachexia in heart failure: mechanisms and therapies , 2017, Nature Reviews Cardiology.

[57]  M. Yalçın,et al.  Immunohistochemical localization of irisin in mole rats (Spalax leucodon) , 2017, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[58]  Oscar L. Sierra,et al.  Skeletal muscle inflammation and atrophy in heart failure , 2017, Heart Failure Reviews.

[59]  Dave L Dixon,et al.  Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. , 2016, Journal of the American College of Cardiology.

[60]  K. Oba,et al.  Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. , 2016, International journal of cardiology.

[61]  M. Febbraio,et al.  The ever-expanding myokinome: discovery challenges and therapeutic implications , 2016, Nature Reviews Drug Discovery.

[62]  U. Wisløff,et al.  Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines? , 2016, Circulation. Heart failure.

[63]  Wook Song,et al.  Effect of aerobic training and resistance training on circulating irisin level and their association with change of body composition in overweight/obese adults: a pilot study. , 2016, Physiological research.

[64]  W. Kraus,et al.  Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[65]  S. Ellefsen,et al.  Irisin in Blood Increases Transiently after Single Sessions of Intense Endurance Exercise and Heavy Strength Training , 2015, PloS one.

[66]  G. Schuler,et al.  Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure—relevance of inflammatory cytokines , 2015, Journal of cachexia, sarcopenia and muscle.

[67]  N. Houstis,et al.  Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The Role of Abnormal Peripheral Oxygen Extraction , 2015, Circulation. Heart failure.

[68]  T. Borchardt,et al.  Myostatin induces interstitial fibrosis in the heart via TAK1 and p38 , 2015, Cell and Tissue Research.

[69]  Wei Wu,et al.  A meta-analysis of proinflammatory cytokines in chronic heart failure , 2014, Heart Asia.

[70]  M. Piepoli,et al.  Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes , 2014, Experimental physiology.

[71]  R. Arena,et al.  Expression of the Irisin Precursor FNDC5 in Skeletal Muscle Correlates With Aerobic Exercise Performance in Patients With Heart Failure , 2012, Circulation. Heart failure.

[72]  T. Murohara,et al.  Therapeutic Impact of Follistatin-Like 1 on Myocardial Ischemic Injury in Preclinical Models , 2012, Circulation.

[73]  G. Schuler,et al.  Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure , 2012, European journal of preventive cardiology.

[74]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[75]  J. Ketelslegers,et al.  Increased plasma myostatin in heart failure , 2011, European journal of heart failure.

[76]  B. Massie,et al.  Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2011, Circulation. Heart failure.

[77]  A. Davenport,et al.  Modulation of the apelin/APJ system in heart failure and atherosclerosis in man , 2010, British journal of pharmacology.

[78]  F. Esposito,et al.  Limited maximal exercise capacity in patients with chronic heart failure: partitioning the contributors. , 2010, Journal of the American College of Cardiology.

[79]  C. Petrilli,et al.  Myostatin activation in patients with advanced heart failure and after mechanical unloading , 2010, European journal of heart failure.

[80]  S. Welle,et al.  Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure , 2010, Circulation.

[81]  G. Schuler,et al.  Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model , 2009, European journal of heart failure.

[82]  M. Caria,et al.  Impaired central hemodynamic response and exaggerated vasoconstriction during muscle metaboreflex activation in heart failure patients. , 2007, American journal of physiology. Heart and circulatory physiology.

[83]  K. Patel,et al.  Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. , 2007, Cardiovascular research.

[84]  G. Schuler,et al.  Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[85]  F. Horkay,et al.  Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. , 2003, Biochemical and biophysical research communications.

[86]  M. Febbraio,et al.  IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle , 2002 .

[87]  G. Schuler,et al.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[88]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[89]  B. Saltin,et al.  Production of interleukin‐6 in contracting human skeletal muscles can account for the exercise‐induced increase in plasma interleukin‐6 , 2000, The Journal of physiology.

[90]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[91]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[92]  M. Koutsilieris,et al.  Effects of High-Intensity Interval Exercise Training on Skeletal Myopathy of Chronic Heart Failure. , 2017, Journal of cardiac failure.

[93]  Katsuhiko Suzuki,et al.  Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. , 2015, Exercise immunology review.

[94]  B. Saltin,et al.  Searching for the exercise factor: is IL-6 a candidate? , 2004, Journal of Muscle Research & Cell Motility.